BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for BMRN
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- joelsg1: @wijimmy $SRPT When their DMD drug was approved initially by FDA over a competing drug from $BMRN, as I recall they overruled staff as it wasn't clear either drug really worked but there was great political pressure from parents of children with this terrible condition for some hopeful cure.. Coming home to roost now.
- woodman: @Dlkayoda $LLY - I think you are referring to the FDA's coming decision (expected this week) on whether to grant accelerated approval to the $BMRN's (and Eisai's) dementia drug lecanemab. I was thinking this news https://www.genprex.com/news/genprex-signs-exclusive-license-to-additional-diabetes-technology-with-the-university-of-pittsburgh/
- woodman: @bla00109 $LLY - I posted about lecanumab without seeing yours. But I think perhaps this is what is affecting $LLY, at least in part: https://www.genprex.com/news/genprex-signs-exclusive-license-to-additional-diabetes-technology-with-the-university-of-pittsburgh/ Regarding the lecanumab, I saw some shops raise BMRN PT's signicantly higher. I think BofA said $200. But also, I saw a negative piece which highlighted prior shenanigans with a BMRN/Eisai trial where the regulator used the wrong protocols which perhaps could cast shade on this attempt for FDA approval. I tend to think it will be approved, but I also don't think this drug is a big step forward (efficacy seems kinda low) and that there is plenty of room for rivals, like $LLY and many others, to find their place in the area. I do have some $BMRN as well.
- woodman: $BMRN up through the 8dEMA. Saw the following "news": BofA PT raised to $200 (was$120) based on: 1) likely US approval of Roctavian (hemA; PDUFA: 3/31) /subsequent initial adoption/ 2) label expansion + broader WW rollout of Voxzogo (achondroplasia). Raised EPS est: '23 $4.15 was $3.9; '24 $8 was $6.25.
- sierramp: @woodman $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR #Biotech Thank you for this. Can't buy them using my usual process for evaluation but very, very interesting so attempting to come up with another way to evaluate. If you have time, would you share how they pass your test?
- woodman: @sierramp $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR #Biotech - Catalysts (trial data due; FDA decisions due, etc.), important therapeutic areas and potential moats, interesting combos with established companies and institutions, strong interest by people I respect. Not all of these necessarily apply to each and every one, but some of these elements apply to each. Not an exhaustive list, but what instantly came to mind. Fwiw, I provided a small bit of color on most of these in a prior recent post here that you can search for. The chart is a factor, but to a more limited extent - less so than my ordinary trading MO.
- pperlroth: @woodman $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR #Biotech These are great! Thank you for sharing as I often look to this industry as the payouts can be massive given potential takeovers AND potential FDA approvals for new drugs/therapies.
- woodman: Updated list of #Biotech that I'm currently in ($$ amounts vary; not in any particular order): $ARDX $ETNB $PDSB $AMLX $ORMP $VKTX $DAWN $BMRN $CPRX $NWBO $SRPT $VRTX $XFOR (bought today).
- woodman: Current #biotech and Big #Pharma that I'm in: $ARDX (gift drop 2 days ago; catalyst with news likely in January - see my prior posts) $CPRX (keeps going) $ORMP (strong today; catalyst into January for P3 results for oral insulin; also, CEO just talke ...
- woodman: $BMRN continues to work well.
- woodman: $BMRN $CPRX - BMRN is extended still, but finding support at the 8dEMA with a pullback and bounce. CPRX holding rising 20d support.
- woodman: $BMRN - I sold most of my shares yesterday, but mid-day today bought most of those sold shares. It's holding up well. Bullish engulfing today with 8dEMA support. But BBs are quite wide, so who knows.
- woodman: $IBB $BMRN - IBB is holding up well. BMRN continues its ascent.
- woodman: $BMRN continues to move up out of messy base. Weekly view shows the potential.
- Lavrock: @woodman $BMRN Company expects that its Hemophilia drug will generate $1BN in revenue within two years of U.S. approval.
- woodman: $BMRN holding up well following news a week ago that a previously scheduled Advisory Committee meeting to assess its hemophilia A drug would no longer take place. More info about this therapy and conditional approval in Europe/road to approval in US here: https://www.marketwatch.com/story/biomarin-fda-drops-plans-for-adcom-meeting-on-hemophilia-a-drug-bmrn-271669211553
- woodman: $BMRN (weekly view is nice) and $BIIB - breakouts. More generally, $IBB is trying too.
- joelsg1: $BMRN Announces FDA no longer insists upon advisory committee review of new Breakthrough Therapy gene therapy hemophilia treatment, already approved in EU. Breaking out on news.
- woodman: @joelsg1 $BMRN - Did you see approval today for $QURE's gene therapy for hemophilia B? I sold mine on this approval pop, but price is higher now than when I sold and it's challenging high of the day.
- joelsg1: @woodman $BMRN $QURE Yes. As I understand it, $QURE is treatment for less common hemophilia B, $BMRN for much bigger market type A.
- woodman: @joelsg1 $BMRN $QURE - Bypassing AdComm seems like a good sign. PDUFA for BMRN's Roctavian is 3/31/23. That old $132 (July 2020) looks like a good magnet.
- joelsg1: @woodman $SRPT Never liked this co. or their MD drug, ever since they beat $BMRN for govt. approval on dubious data. Almost any new drug would do better. Good riddance.
- woodman: @joelsg1 $SRPT $BMRN - I thought if it could breakout to the upside, it could fill the rest of the gap up to 161 possible, but I didn't trust it which is why I sold most before earnings. Managed a profit but was hoping for much more. Oh well.
- joelsg1: @woodman $SRPT $BMRN Book it Dano! (Old Hawaii 5 0 reference)
- woodman: @joelsg1 $SRPT $BMRN - I'm old enough to recall the reference. (Unfortunately.)
- RD: $BMRN @scottrades BMRN continues to recover from earnings sell off yesterday. Any thoughts?
- scottrades: @RD $BMRN I guess you could use yesterdays low as a stop level but it's not one of my go-to setups.
- RD: @scottrades $BMRN Thank you Scott!
- mharps: $BMRN add snall
- issues: @mharps $BMRN Thank you for mentioning this one. I also bought it and $MRNA. I put in a limit order on $AMLX. Also we own $VRTX which reports tonight AH . All these are in the IBD group 10 Biomed. Good group to be in.
- woodman: This is a list of #Gene editing/therapy #Car-T stocks (#Biotech subset). I haven't updated it in some time, so it's not an up-to-date/complete list, but it provides a number stocks that are acting very well and, if you've paid any attention to this area over the years, you'll certainly recognize many of them (including $NTLA which @Dan added to his list today). If interested, kick some of their tires over the weekend (listed below in order of performance today). $ABEO $ADVM $EIGR $PGEN $QURE $RARE $AGTC $SRNE $BLUE $PRTA $CLLS $AVRO $MGTX $ADAP $KRYS $SRPT $BMRN $AMGN $ARCT $RGNX $CNCR $SLDB $TCRT $AGIO $NVS $JNJ $PFE $IOVA $NTLA $SGMO $LUMO $EDIT $VYGR $ORTX $CRSP $BLCM $BBIO
- 1993dean: $BMRN
- 1993dean: $BMRN braking downward trend line.
- sierramp: $BMRN getting some volume.
- joelsg1: @sierramp $BMRN Stifel upgrade to $96. After the DMD debacle, they need another win.
- scottto_2: #InsideBarList - My OCD kicked in hard on this one - Thanks Sir @Aragorn - $AAL $AAOI $AAPL $ABC $ABT $ABUS $ACAD $ADI $ADS $AEM $AES $AFL $AGCO $AGIO $AIG $AKAM $AKTX $ALE $ALGT $AMCX $AMN $AMP $AMT $AMZN $AN $ANET $ANGI $ANTM $AON $APA $APD $APRN $ ...
- giants: @giants $BRMN make that $BMRN
- joelsg1: @Henry $SRPT Same thing happened to its former competitor $BMRN. Tough disease.
- Ajax4Hire: Yes, $MRNA-Moderna(a CoronaVirus vaccine developer) is in the $IBB. Looks like $MRNA, $NVCR and $TECH is the real reason $IBB looks so appealing. Hold% $IBB iShares Nasdaq Biotechnology ETF - Top 15 holdings 7.31% $GILD Gilead Sciences, Inc. 7.13% $AMGN Amgen Inc. 6.02% $VRTX Vertex Pharmaceuticals Incorporated 5.63% $REGN Regeneron Pharmaceuticals, Inc. 4.70% $ILMN Illumina, Inc. 4.62% $MRNA Moderna, Inc. 3.45% $BIIB Biogen Inc. 3.09% $SGEN Seagen, Inc. 2.89% $ALXN Alexion Pharmaceuticals, Inc. 1.90% $INCY Incyte Corporation 1.61% $HZNP Horizon Therapeutics Public Limited Company 1.56% $ALNY Alnylam Pharmaceuticals, Inc 1.52% $BMRN BioMarin Pharmaceutical Inc. 1.26% $NVCR NovoCure Ltd. 1.25% $TECH Bio-Techne Corporation Data from: https://ETFdB.com/etf/IBB/#holdings
- pointbob: $BMRN deadcat bouncing. Decent vol on the upticks.
- Herb: $BMRN escaped a bullet. Thought about buying it on Monday. . . . .
- 86944T: @Herb $BMRN That dead cat isn’t bouncing, so far. May have embedded in the pavement.
- joelsg1: @Herb $BMRN Been in this for years, though fortunately out recently as posted. Originally got in because of promising duchenne muscular dystrophy drug. Zoomed up to 150 then cut in half as $SRPT had the approved drug. Now, same thing seems to be happening with hemophilia franchise. So, fool me once...
- Herb: $BMRN showing a pulse. Has now recaptured the 8 EMA but is still caught below the 50 DMA. Just watching. . . . .
- HGIGuy: $BMRN Reports earnings this afternoon. Sitting just above support at 50dma.
- joelsg1: $BMRN Sold on small bounce this am. Big gain, better opportunities elsewhere.
- vatradergreg: Engaging $BMRN on the breakout. NOT huge volume today, but super strong trend. 150 Target stop below the 8MA.
- joelsg1: @vatradergreg $BMRN In from way below. Painful hold for awhile but strong move since 97 in channel with bottom at 20 day.
- vatradergreg: @joelsg1 $BMRN - nice job! I'm chasing a little. Main reason for my tight stop.
- traderdl: $BMRN spike ATH
- HGIGuy: @traderdl $BMRN Big volume spike at 2pm. Same with $RH. Specific stocks jumped with release of #FedMinutes, but I haven't discovered the common factor yet.
- HGIGuy: $BMRN rebounding nicely. Near four year high.
- Ajax4Hire: Bio-Technology; Bio=Life; Techno=art/craft/skill; logy=study of BioTechnoLogy=Life-Craft-Study, aren't we all bio-technologist. Hold% $IBB iShares Nasdaq Biotechnology ETF - Top 15 holdings 7.93% $AMGN Amgen Inc 7.87% $VRTX Vertex Pharmaceuticals Inc 7.45% $GILD Gilead Sciences Inc 6.51% $REGN Regeneron Pharmaceuticals Inc 5.54% $ILMN Illumina Inc 3.37% $BIIB Biogen Inc 3.11% $SGEN Seattle Genetics Inc 2.68% $ALXN Alexion Pharmaceuticals Inc 2.57% $MRNA Moderna Inc 2.43% $INCY Incyte Corp 2.31% $BMRN Biomarin Pharmaceutical Inc 1.83% $ALNY Alnylam Pharmaceuticals Inc 1.38% $SRPT Sarepta Therapeutics Inc 1.24% $NBIX Neurocrine Biosciences Inc 1.21% $SNY Sanofi SA Data from: https://ETFdB.com/etf/IBB/#holdings
- Ajax4Hire: And the complement; $XBI Bio-Technology; Bio=Life; Techno=art/craft/skill; logy=study of BioTechnoLogy=Life-Craft-Study, aren't we all bio-technologist. Hold% $XBI SPDR S&P Biotech ETF - Top 15 holdings 1.79% $NVTA Invitae Corp 1.60% $INO Inovio Pharmaceuticals Inc 1.48% $NVAX Novavax Inc 1.38% $FOLD Amicus Therapeutics Inc 1.23% $ARWR Arrowhead Pharmaceuticals Inc 1.19% $MNTA Momenta Pharmaceuticals Inc 1.17% $ALNY Alnylam Pharmaceuticals Inc 1.16% $EDIT Editas Medicine Inc 1.15% $SAGE SAGE Therapeutics Inc 1.14% $DCPH Deciphera Pharmaceuticals Inc 1.14% $IMMU Immunomedics Inc 1.14% $KPTI Karyopharm Therapeutics Inc 1.13% $ALKS Alkermes Plc 1.12% $INCY Incyte Corp 1.11% $BMRN Biomarin Pharmaceutical Inc Data from: https://ETFdB.com/etf/XBI/#holdings
- HGIGuy: $BMRN breaking out
- cgendro1: @HGIGuy $BMRN Took a position a couple days ago. the weekly view is my guide :)
- cgendro1: $BMRN- ATH in a down tape. Up 5%
- CdrJake: $GNMK $DVAX working, heavy volume today, twice avg for both. $APT nearly triple volume. COVID-19 trades. $LGND $BMRN good day for last 10 minutes also...Serious option witching pressures
- cgendro1: $BMRN- took a starter. up almost 4% today. Vol on up days better than down. Number 5 ranked industry group and #1 in the group. I'll add on take out of 112. Wkly chart good noting sideways consolidation for about 2.5 yrs! Looks poised to move up
- HGIGuy: $BMRN Finally breaking out, near ATH
- Bert953: @HGIGuy $BMRN missed it, now @ R1
- HGIGuy: @cgendro1 $BMRN #1 Started position yesterday @107
- joelsg1: @Bert953 $BMRN Posted previously about breakout through 97, now through 112 on way back to old high 150s. Penalized for losing to $SRPT on muscular dystrophy but strong hemophilia franchise plus pipeline.
- cgendro1: @HGIGuy $BMRN #1 Always nice to have good company :)
- joelsg1: $BMRN Moving again, broke through resistance at 97 and hasn't looked back, now 111 and counting.
- joelsg1: $BMRN Breaks through resistance with volume on $SNY takeover rumor but heading there regardless
- joelsg1: $BMRN breaking up through resistance, next stop 107 level from Fall 2018
- joelsg1: $BMRN Buying this breakout
- spmeyers: @joelsg1 $BMRN not a breakout on daily chart; day 3 of move, weak volume; be careful
- joelsg1: @spmeyers $BMRN True, but added to existing position. Tight stop though.
- CdrJake: @joelsg1 $BMRN IDid you mean the rebound off the 50 DMA on daily chart, (which was a test of the breakout from the cup and handle between 3/12 and 4/6); or the move above the VWAP? Not really a breakout until it gets past 99. 60.
- joelsg1: @CdrJake $BMRN Started at bounce off 50 day @86, adding above vwap, watching former double top @ 97
- 1993dean: $AMZN A BUY DOWN HERE WATCH $BMRN
- Ajax4Hire: @scottrades $IBB IBB iShares Nasdaq Biotechnology ETF 8.57% $AMGN - Amgen Inc 8.12% $GILD - Gilead Sciences Inc 7.55% $VRTX - Vertex Pharmaceuticals Inc 6.27% $ILMN - Illumina Inc 5.15% $BIIB - Biogen Inc 4.75% $REGN - Regeneron Pharmaceuticals Inc 3.47% $ALXN - Alexion Pharmaceuticals Inc 2.88% $SGEN - Seattle Genetics Inc 2.69% $INCY - Incyte Corp 1.95% $BMRN - Biomarin Pharmaceutical Inc 1.75% $ALNY - Alnylam Pharmaceuticals Inc 1.47% $NBIX - Neurocrine Biosciences Inc 1.28% $NVCR - Novocure Ltd 1.27% $MYL - Mylan NV 1.20% $IONS - Ionis Pharmaceuticals Inc 58.4% Top 15 holdings
- indigo1948: @traderbren $IWM - entered $BMRN yesterday after you brought it up in the forum - thank you for the heads up. Volatile but promising
- traderbren: @indigo1948 $IWM $BMRN - great! Just maintain a trailing stop. Cheers.
- traderbren: $BMRN - pushing back above the 50d.
- traderbren: $BMRN - back above the 20d. NP
- issues: I prefer ibb to xbi. I am thinking of selling $XBI and buying $IBB. I like the stocks better in the IBB portfolio ($CELG $REGN $VRTX $ALXN $BMRN ...) But with IBB at a top I might wait on this to buy it. I have a full position in $HAE and it report 2/5. Put in a partial stop at $94.5. I don't like the downward chart but I see every time they report the stock jumps up. Debeers is ma' main man for HAE. Are you Ms Debeers?
- shoredriver: FWIW Doc Naj on Fasthalf mentioned very heavy call buying in $BMRN Jan115's, as well as Feb120's....lost track of this one and it is back on my radar ........Not usually a factor for Biotechs but earnings are 1/24....
- woodman: For what little it may be worth: GS #Biotech stocks where GS analysts see the highest M&A probability: $BLUE $BMRN $BPMC $CLVS $CRSP $INCY $MDGL $PCRX $PTLA $RVNC $SAGE $SRPT
- shoredriver: @woodman $BLUE $BMRN $BPMC $CLVS $CRSP $INCY $MDGL $PCRX $PTLA $RVNC $SAGE $SRPT #Biotech .....$CLVS.....ugly memory.......
- woodman: @shoredriver $BLUE $BMRN $BPMC $CLVS $CRSP $INCY $MDGL $PCRX $PTLA $RVNC $SAGE $SRPT #Biotech - BMRN has been on that list forever. Broken clock. Eventually they will be right about it getting bought.
- gwenzee: @woodman $BLUE $BMRN $BPMC $CLVS $CRSP $INCY $MDGL $PCRX $PTLA $RVNC $SAGE $SRPT #Biotech I've been waiting for someone to scoop up INCY for quite awhile. At least it has come off of the recent lows. Someone is throwing me a lifeline which I really need on this one.
- traderbren: $BMRN -- looking constructive here. NP.
- gwenzee: $ONCE Leerink raised target price from $55 to $74. Hemophilia drug is on the horizon. Projected cost is $1,000,000 to $1,500,000 per treatment. Sounds like a lot until you compare yearly cost to patients of over $800,000/yr. The gene therapy drug, like Luxturna, is a one-time cost for a cure. They are competing with $QURE and $BMRN.
- woodman: @gwenzee $ONCE $QURE $BMRN - That's some serious sticker shock.
- woodman: @gwenzee $ONCE $QURE $BMRN - ONCE is at a decent spot on this pullback to and bounce the 200 / 50 days, but the PT raise is $1 above its current price. I don't put much faith in PTs anyway, except for the immediate (and often temporary) knee-jerk responses elicited by their announcements.
- gwenzee: @woodman $ONCE $QURE $BMRN Guess you have to put it into perspective. How many drugs offer a cure after only one treatment?
- woodman: @gwenzee $ONCE $QURE $BMRN - earnings tomorrow morning. I like the chart here, but will wait.
- bsafriet: $BMRN Target $90.00. Long Apr-20 $85 calls
- peppercorn: @Aragorn thanks for these #InsideMonths to consider and track for FEB 2018 - $ADXS $AGCO $AGX $ALNY $ALRM $APT $ATAI $AVAV $BCOV $BLUE $BMRN $CALA $CGNX $CLX $CRTO $DBA $DBD $EFOI $EQT $EYES $GBTC $GLUU $GNC $HQY $IBP $INVE $JJC $KMG $KSU $LAKE $LL $MBI $MDC $MEI $MMC $NTES $OAS $ONCE $ONVO $PAY $PCG $PRTA $PTLA $QRVO $SAIC $SDRL $SFUN $SNAP $SPWR $SWKS $T $TELL $TGI $TRIL $TROV $TROX $USCR $WATT $XOMA $XONE
- woodman: @gwenzee $JUNO $RXDX #Biotech $BLUE up ~7% in the afterhours. Biotech will jump tomorrow. Fwiw, GS sees these as having the highest M&A probability in biopharma (some of these are perennial buyout names): $AVXS $SAGE $SRPT $BMRN $BLUE $BMPC $CLVS $INCY $IPXL $PCRX $PTLA $ACAD $GWPH $BMY $IRWD $AGIO $ALKS $JUNO $SGEN $MNTA $BIVV.
- gwenzee: @woodman $JUNO $RXDX $BLUE $AVXS $SAGE $SRPT $BMRN $BMPC $CLVS $INCY $IPXL $PCRX $PTLA $ACAD $GWPH $BMY $IRWD $AGIO $ALKS $SGEN $MNTA $BIVV #Biotech Thanks for the info. Previously held JUNO, BLUE, SRPT. Currently hold only INCY.
- indigo1948: $BMRN = one of many biotech issues on the move today .
- issues: I just read a very encouraging article by Mike Brush (Brush Up On Stocks) from Market Watch: http://www.marketwatch.com/story/10-biotech-companies-ripe-for-a-buyout-courtesy-of-donald-trump-2016-11-17 The article is entitled "MW 10 Biotechcompanies Ripe for Buyouts Courtesy of Donald Trump". There are lots of reasons why a Trump administration is going to push biotechs up higher. The list for buyouts includes $BIIB $INCY $TSRO $IONS $MDCO $ACAD as buyout candidates. Others mentioned included $BMRN $AZN.LN. Finally the article said that with Prop 61 failing in the most liberal state (Cal) that would have limited drug prices, the biotechs can price in increases. Also mentioned JNJ MRK PFE. Nov/Dec biggest for biotech all year. Companies with drugs that have minimal competition include: $VRTX $SRPT $CELG $ALXN. We own $VRTX$ IONS $CELG $ALXN and $IBB
- sincity45: $BMRN looks like it reversed after filling the gap, long tail. BTO NOV 16 $85 call.
- TunaHelper: Looking at $BMRN to see if it bounces off the 50dma.
- stevef214: $BMRN $LABU added to both this morning as they were up and winners. Now both losers. $NUGT had a small position yesterday with a conditional order for stop loss but did not trigger due to I had a limit on the sell loss. Not a good day to say the least
- stevef214: $BMRN started position at open BTO 9/16 $90 Call for $9.30
| Stock Price | $82.13 |
| Change | 1.51% |
| Volume | 2,008,730 |
Biomarin Pharmaceutical, Inc., develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Request Video of BMRNAlready a member? Sign in here.
Past Month
Leading Peers
-
$12.76 309.10%
-
$6.18 273.76%
-
$12.32 258.96%
Past Month
Lagging Peers
-
$28.29 -78.88%
-
$6.26 -75.21%
-
$13.82 -57.99%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!